Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders

6533b874fe1ef96bd12d6106

RESEARCH PRODUCT

Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders

Carlo Federico Perno Andreas Tiede Lutz G Prof Dr Guertler James W. Ironside David Navarro Di Minno Giovanni Mariana Canaro

subject

0301 basic medicine riesgo humanos Ultrafiltration Bacteremia Blood Donors Hepacivirus 030204 cardiovascular system & hematology Parasitemia /dk/atira/pure/subjectarea/asjc/2700/2720 0302 clinical medicine Blood plasma Screening method Medicine Pathogen Chromatography ultrafiltración fungemia Transmission (medicine)Blood Screening bacteriemia Hematology Blood Coagulation Disorders Chromatography Ion Exchange Settore MED/07 - Microbiologia e Microbiologia Clinica transfusión de componentes sanguíneos /dk/atira/pure/subjectarea/asjc/2700/2730 trastornos de la coagulación sanguínea Oncology VIH-1 Risk Hepatitis B virus Haemophilia Blood Component Transfusion Haemophilia Article patógenos transmitidos por la sangre 03 medical and health sciences Blood-Borne Pathogens Humans Viremia cromatografía Blood safety; Clotting; Haemophilia; Pathogen; Transfusion Pathogen business.industry Donor selection Transfusion Clotting donantes de sangre virus de la hepatitis B medicine.disease Residual risk 030104 developmental biology Immunology HIV-1 business Blood safety

description

The pathogen safety of blood/plasma-derived products has historically been a subject of significant concern to the medical community, Measures such as donor selection and blood screening have contributed to increase the safety of these products, but pathogen transmission does still occur. Reasons for this include lack of sensitivity/specificity of current screening methods, lack of reliable screening tests for some pathogens (e.g. prions) and the fact that many potentially harmful infectious agents are not routinely screened for. Methods for the purification/inactivation of blood/plasma-derived products have been developed in order to further reduce the residual risk, but low concentrations of pathogens do not necessarily imply a low level of risk for the patient and so the overall challenge of minimising risk remains. This review aims to discuss the variable level of pathogenic risk and describes the current screening methods used to prevent/detect the presence of pathogens in blood/plasma-derived products.

year	journal	country	edition	language
2015-07-01	Blood Reviews

https://doi.org/10.1016/j.blre.2015.07.004